Common
- Symbol
- STAA
- Exchange
- NASDAQ
- Classification
- OTHER
- Status
- Current
Current Report · Items 2.02, 7.01, 9.01 · 8-K
STAANASDAQEQUITYCurrent
Item 2.02 Results of Operations and Financial Condition. On November 4, 2026, STAAR Surgical Company (the “Company”) published a press release reporting its financial results for the quarter ended October 2, 2026, a copy of which is furnished as Exhibit 99.1 to this report and is incorporated herein by this reference.
Press release in this filing
STAAR Surgical Reports Third Quarter 2026 Results →STAAR Surgical (NASDAQ: STAA) is the global leader in implantable phakic intraocular lenses, a vision correction solution that reduces or eliminates the need for glasses or contact lenses. Since 1982, STAAR has been dedicated solely to ophthalmic surgery, and for over 30 years, STAAR has been designing, developing, manufacturing, and marketing advanced Implantable Collamer® Lenses (ICLs), using its proprietary biocompatible Collamer material. STAAR ICLs are clinically proven to deliver safe long-term vision correction without removing corneal tissue or the eye's natural crystalline lens. Its EVO ICL™ product line provides visual freedom through a quick, minimally invasive procedure.
STAAR SURGICAL CO · 8-K · Filed 2026-11-04
Exhibit 99.1 STAAR Surgical Reports Third Quarter 2026 Results Net Sales of $83.4 Million in the Third Quarter Net Income of $5.6 Million, with GAAP EPS of $0.11 Adjusted EBITDA[1]of $14.4 Million, or $0.28 per Diluted Share Record Revenue of $270.5 Million in the First Three Quarters Net Income of $18.8 Million, or $0.37 per Diluted Share, in the First Three Quarters Adjusted EBITDA[1] of $58.8 Million, or $1.14 per Diluted Share, in the First Three Quarters LAKE FOREST, Calif. --(BUSINESS WIRE)--STAAR Surgical Company (“STAAR” or the “Company”) (NASDAQ: STAA), the global leader in phakic IOLs with the EVO™ family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the third quarter ended October 2, 2026. The Company will host an earnings call and webcast today at 5:30 PM Eastern Time. Third Quarter and Year-to-Date 2026 Highlights Include: • Net sales down 12% Y/Y; up 21% excluding a 33-percentage point ($25.9 million) impact from previously deferred China sales recognized in the third quarter of 2025 • China sales of $39.3 million, down 30% Y/Y; up 31% excluding a 61-percentage point impact from the deferred China sales • EMEA…
Open exhibit ↗